Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Travel4Expertise – The Grant for Caregivers

May 17, 2024Gender Equality Committee (GEC)

HOST AN IN-PERSON
IUIS IMMUNOLOGY
COURSE IN 2025

May 8, 2024Education Committee (EDU)

Michelson Prizes: Next Generation Grant

April 30, 2024Early Career Committee (ECC)

IUIS Junior Community: Pushing the Frontiers of Immunology

April 19, 2024Early Career Committee (ECC)

2024 Day of Immunology Webinar registration is live!

March 15, 2024

Call for Applications to join the IUIS Gender Equality Committee

March 1, 2024Gender Equality Committee (GEC)

IUIS/AAI AWARDS: SUMMER COURSES in IMMUNOLOGY

February 8, 2024American Association of Immunologists (AAI), Gender Equality Committee (GEC) and 1 more

Calling for Nominations to the EDU Committee & its online subcommittee

November 7, 2023Education Committee (EDU)

Statement on Middle East

October 27, 2023